TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
Tonix Pharmaceuticals Holding Corp. (the Company) intends to
utilize an updated investor presentation to conduct meetings with
investors, stockholders and analysts and at investor conferences,
and which the Company intends to place on its website, which may
contain non-public information.A copy of the presentation is
filed as Exhibit 99.01.
The information contained in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.01, is furnished to, and shall not
be deemed to be filed for the purposes of, Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section.The information contained in
Item 7.01 of this Current Report shall not be incorporated by
reference into any registration statement or any other document
filed to the Securities Act of 1933, as amended, except as
otherwise expressly stated in such filing.By filing this Current
Report on Form 8-K and furnishing the information contained in
this Item 7.01, including Exhibit 99.01, the Company makes no
admission as to the materiality of any such information that it
is furnishing.
| Item 8.01 | Other Events. |
On December 8, 2016, the Company issued a press release
announcing that the Company presented an updated poster,
entitled, The AtEase Study: A Phase 2 Multicenter Randomized
Clinical Trial of the Safety and Efficacy of TNX-102 SL in the
Treatment of Military-Related PTSD (the Poster), at the
55thAnnual Meeting of the American College of
Neuropsychopharmacology held in Hollywood, Florida. The Poster
was presented by Dr. Gregory Sullivan, M.D., the Companys chief
medical officer.
A copy of the press release that discusses this matter is filed
as Exhibit 99.03 to, and incorporated by reference in, this
report. The foregoing description of the Poster is qualified in
its entirety by reference to the Poster, a copy of which is
deemed filed as Exhibit99.02 to, and is incorporated by reference
in, this report.
The information in this Current Report is being furnished and
shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, except as shall be expressly set forth by specific
reference in any such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.01 | Corporate Presentation by the Company for December 2016* |
| 99.02 |
The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX-102 SL in the Treatment of Military-Related PTSDPoster, filed as an exhibit to the Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 7, 2016 and incorporated herein by reference* |
| 99.03 |
Press Release, dated December 8, 2016, issued by Tonix Pharmaceuticals Holding Corp.* |
* Furnished herewith.
About TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP)
